The impact of marginalization on diffuse large B-cell lymphoma overall survival: a retrospective cohort study
Arya S, Mozessohn L, Gong I, Faught N, Liu N, Singh S, Chan K, Cheung MC. Leuk Lymphoma. 2024; Jan 24 [Epub ahead of print].
Publications
Machine learning–based early warning systems for acute care utilization during systemic therapy for cancer
Grant RC, He JC, Khan F, Liu N, Podolsky S, Kaliwal Y, Powis M, Notta F, Chan KKW, Ghassemi M, Gallinger S, Krzyzanowska MK. J Natl Compr Canc Netw. 2023; 21(10):1029–37.e21. Epub 2023 Oct 1.
Changes in healthcare costs, survival, and time toxicity in the era of immunotherapy and targeted systemic therapy for melanoma
Bateni SB, Nguyen P, Eskander A, Seung SJ, Mittmann N, Jalink M, Gupta A, Chan KKW, Look Hong NJ, Hanna TP. JAMA Dermatol. 2023; Sep 6 [Epub ahead of print].
SARS-CoV-2 infection, hospitalization, and mortality in adults with and without cancer
Hosseini-Moghaddam SM, Shepherd FA, Swayze S, Kwong JC, Chan KKW. JAMA Netw Open. 2023; 6(8):e2331617. Epub 2023 Aug 31.
Mortality among patients with diffuse large B-cell lymphoma with mental disorders: a population-based study
Gong I, Cheung MC, Chan KKW, Arya S, Faught N, Calzavara A, Liu N, Odejide OO, Abel G, Kurdyak P, Raphael MJ, Kuczmarski T, Prica A, Mozessohn L. J Natl Cancer Inst. 2023; Aug 2 [Epub ahead of print].
Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario
Suleman A, Aktar SJ, Ante Z, Liu N, Chan KKW, Cheung MC, Prica . Br J Haematol. 2023; Jul 20 [Epub ahead of print].
Association between the COVID-19 pandemic and first cancer treatment modality: a population-based cohort study
Fu R, Sutradhar R, Li Q, Hanna TP, Chan KKW, Irish JC, Coburn N, Hallet J, Dare A, Singh S, Parmar A, Earle CC, Lapointe-Shaw L, Krzyzanowska MK, Finelli A, Louie AV, Look Hong NJ, Witterick IJ, Mahar A, Urbach DR, McIsaac DI, Enepekides D, Eskander A. CMAJ Open. 2023; 11(3):E426-33. Epub 2023 May 9.
Cost-effectiveness of second-line ipilimumab for metastatic melanoma: a real-world population-based cohort study of resource utilization
Lu B, Dai WF, Croxford R, Isaranuwatchai W, Beca J, Menjak IB, Petrella TM, Mittmann N, Earle CC, Gavura S, Mercer RE, Hanna TP, Chan KKW. Cancer Med. 2023; 12(10):11451-61. Epub 2023 Mar 31.
Early survival for patients newly diagnosed with cancer during COVID-19 in Ontario, Canada: a population-based cohort study
Fu R, Sutradhar R, Li Q, Kalraj P, Dare A, Hanna TP, Chan KKW, Irish JC, Coburn N, Hallet J, Singh S, Parmar A, Earle CC, Lapointe-Shaw L, Krzyzanowska MK, Louie AV, Mahar A, Urbach DR, McIsaac DI, Enepekides D, Gomez D, Look Hong NJ, Tinmouth J, Eskander A. Cancer Med. 2023; 12(10):11849-59. Epub 2023 Mar 31.
Timeliness and modality of treatment for new cancer diagnoses during the COVID-19 pandemic in Canada
Fu R, Sutradhar R, Li Q, Hanna TP, Chan KKW, Irish JC, Coburn N, Hallet J, Dare A, Singh S, Parmar A, Earle CC, Lapointe-Shaw L, Krzyzanowska MK, Finelli A, Louie AV, Look Hong NJ, Witterick IJ, Mahar A, Urbach DR, McIsaac DI, Enepekides D, Tinmouth J, Eskander A. JAMA Netw Open. 2023; 6(1):e2250394. Epub 2023 Jan 10.